ethyl 4-(chloroacetyl)-phenylacetate | 7706-78-7

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: ethyl 4-(chloroacetyl)-phenylacetate
• 英文别名: (4-chloroacetyl-phenyl)-acetic acid ethyl ester；(4-Chloracetyl-phenyl)-essigsaeure-aethylester；ethyl 4-(chloroacetyl)phenylacetate；ethyl 4-chloroacetylphenylacetate；4-Chloracetyl-phenylessigsaeure-aethylester；ethyl 2-[4-(2-chloroacetyl)phenyl]acetate
• CAS: 7706-78-7
• 化学式: C₁₂H₁₃ClO₃
• 分子量: 240.686
• InChiKey: CDIIBXLDZABFRK-UHFFFAOYSA-N

物化性质

• 沸点：
  355.1±27.0 °C(Predicted)
• 密度：
  1.193±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.4
• 重原子数：
  16
• 可旋转键数：
  6
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  43.4
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  ethyl 4-(chloroacetyl)-phenylacetate 在 sodium azide 、 苄基三甲基氯化铵 作用下， 以 二氯甲烷 为溶剂， 生成 ethyl 4-(azidoacetyl)phenylacetate
  参考文献：
  名称：

  DD127474

  摘要：

  公开号：
• 作为产物：
  描述：

  (4-chloroacetyl-phenyl)-acetonitrile 在 盐酸 作用下， 生成 ethyl 4-(chloroacetyl)-phenylacetate
  参考文献：
  名称：

  Kunckell, Chemische Berichte, 1908, vol. 41, p. 3047

  摘要：

  DOI：

文献信息

• Heterocyclic derivatives
  申请人：Zeneca Limited

  公开号：US05556977A1

  公开（公告）日：1996-09-17

  Compounds of formula I ##STR1## and metabolically labile esters and amides thereof, and pharmaceutically acceptable salts thereof, in which R.sup.13, M.sup.2, X.sup.1, Z.sup.1, Z.sup.1a, X.sup.2 and A.sup.1 have the meanings given in the specification. The compounds are useful as inhibitors of the binding of fibrinogen to glycoprotein IIb/IIIa. Intermediates are also disclosed.

  公式I的化合物及其代谢易降解的酯和酰胺，以及其药学上可接受的盐，其中R.sup.13，M.sup.2，X.sup.1，Z.sup.1，Z.sup.1a，X.sup.2和A.sup.1具有规范中给定的含义。这些化合物可用作抑制纤维蛋白原与糖蛋白IIb/IIIa结合的抑制剂。还披露了中间体。
• Heterocyclic compouds
  申请人：Zeneca Limited

  公开号：US05753659A1

  公开（公告）日：1998-05-19

  A compound of the general formula (M.sup.1).sub.n --Q--(M.sup.2).sub.1-n --L--A I wherein: n is 0 or 1; M.sup.1 is an amino group; Q is an aromatic heterocyclic group containing a basic nitrogen atom; M.sup.2 is an imino group; L is a template group; and A is an acidic group, or an ester or amide derivative thereof, or a sulphonamide group; and pharmaceutically acceptable salts and pro-drugs thereof, for use in the treatment of a disease in which platelet aggregation mediated by the binding of adhesion molecules to GPIIb-IIIa is involved. Novel compounds are also disclosed.

  通式（M.sup.1).sub.n --Q--(M.sup.2).sub.1-n --L--A I的化合物，其中：n为0或1；M.sup.1为氨基；Q为含有碱性氮原子的芳香杂环基团；M.sup.2为亚胺基；L为模板基团；A为酸性基团，或其酯或酰胺衍生物，或磺酰胺基团；以及其药学上可接受的盐和前药，用于治疗通过粘附分子结合到GPIIb-IIIa介导的血小板聚集参与的疾病。还披露了新的化合物。
• .alpha.-Amino ketone derivatives
  申请人：Imperial Chemical Industries Limited

  公开号：US04105790A1

  公开（公告）日：1978-08-08

  The invention concerns .alpha.-aminoacyl derivatives of phenyl-, phenoxy-, thiophenoxy- and phenylsulphinylalkanoic acids together with their amides, esters and pharmaceutically acceptable salts; processes for their preparation; and pharmaceutical compositions for therapeutic use in inhibiting the formation of thrombi and also in reducing the persistence of thrombi formed in the blood of warm blooded animals. Representative compounds of the invention are methyl 4-(aminoacetyl)phenoxyacetate, 4-(aminoacetyl)phenoxyacetic acid and methyl 4-(aminoacetyl)-thiophenoxyacetate, preferably as their hydrochlorides.

  该发明涉及苯基、苯氧基、硫代苯氧基和苯基磺基烷酸的α-氨基酰衍生物，以及它们的酰胺、酯和药用盐；它们的制备方法；以及用于在温血动物的血液中抑制血栓形成并减少已形成血栓持续存在的治疗用药物组合物。该发明的代表性化合物包括甲基4-(氨基乙酰)苯氧乙酸酯、4-(氨基乙酰)苯氧乙酸和甲基4-(氨基乙酰)-硫代苯氧乙酸酯，最好以它们的盐酸盐形式。
• Substituted phenylalkanoic acids and derivatives
  申请人：Yoshitomi Pharmaceutical Industries, Ltd.

  公开号：US03978071A1

  公开（公告）日：1976-08-31

  Substituted phenylalkanoic acids and derivatives thereof of the formula: ##SPC1## Wherein each of R.sup.1 and R.sup.2 is a hydrogen atom or an alkyl group having 1 to 4 carbon atoms; each of X.sup.1 and X.sup.2 is a hydrogen atom, a halogen atom, an alkyl group having 1 to 4 carbon atoms or an alkoxy group having 1 to 4 carbon atoms; Y is COOH, COOR (wherein R is an alkyl group having 1 to 4 carbon atoms), CONH.sub.2, CSNH.sub.2, CN or COZ--A--N(R.sup.3)(R.sup.4) (wherein Z is an oxygen atom or an imino group, A is an alkylene group having 2 to 4 carbon atoms and each of R.sup.3 and R.sup.4 is a hydrogen atom or an alkyl group having 1 to 4 carbon atoms, or R.sup.3 and R.sup.4 together with the adjacent nitrogen atom form a saturated heterocycle selected from pyrrolidine, piperidine, morpholine, piperazine and piperazine substituted by an alkyl group having 1 to 4 carbon atoms at the 4-position; and ring P represents a pyridine ring, a pyrimidine ring or a thiazole ring; and pharmaceutically acceptable salts thereof are useful as analgesics, anti-pyrestics and anti-inflammatory agents.

  具有以下式子的取代苯基脂肪酸及其衍生物：##SPC1## 其中，R1和R2中的每一个均为氢原子或具有1至4个碳原子的烷基；X1和X2中的每一个均为氢原子、卤素原子、具有1至4个碳原子的烷基或具有1至4个碳原子的烷氧基；Y为COOH、COOR（其中R为具有1至4个碳原子的烷基）、CONH2、CSNH2、CN或COZ-A-N(R3)(R4)（其中Z为氧原子或亚胺基，A为具有2至4个碳原子的烷基，R3和R4中的每一个均为氢原子或具有1至4个碳原子的烷基，或R3和R4与相邻的氮原子一起形成选择自吡咯烷、哌嗪烷、吗啉、哌嗪和哌嗪在4位上取代具有1至4个碳原子的烷基的饱和杂环；环P代表吡啶环、嘧啶环或噻唑环；以及其药学上可接受的盐作为镇痛剂、解热剂和抗炎药物具有用途。
• Heterocyclic derivatives as platelet aggregation inhibitors
  申请人：ZENECA LIMITED

  公开号：EP0825184A1

  公开（公告）日：1998-02-25

  RS 3-Methyl-4-[4-(4-pyridyl)piperazin-1-yl]phenoxybutyric acid and metabolically labile ester or amides thereof, and pharmaceutically acceptable salts thereof useful as an inhibitor of the binding of fibrinogen to glycoprotein IIb/IIIa.

  RS 3-甲基-4-[4-(4-吡啶基)哌嗪-1-基]苯氧基丁酸及其代谢易变酯或酰胺，以及可用作纤维蛋白原与糖蛋白 IIb/IIIa 结合抑制剂的药学上可接受的盐。